Abstract:Introduction: Critically ill patients are at risk of suboptimal beta-lactam antibiotic (beta-lactam) exposure due to the impact of altered physiology on pharmacokinetics. Suboptimal concentrations can lead to treatment failure or toxicity. Therapeutic drug monitoring (TDM) involves adjusting doses based on measured plasma concentrations and individualising dosing to improve the likelihood of improving exposure. Despite its potential benefits, its adoption has been slow, and data on implementation, dose adaptation and safety are sparse. The aim of this trial is to assess the feasibility and fidelity of implementing beta-lactam TDM-guided dosing in the intensive care unit setting. Methods and analysis: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring (ADAPT-TDM) is a single-centre, unblinded, feasibility randomised controlled trial aiming to enroll up to 60 critically ill adult participants (≥18 years). TDM and dose adjustment will be performed daily in the intervention group; the standard of care group will undergo plasma sampling, but no dose adjustment. The main outcomes include: (1) feasibility of recruitment, defined as the number of participants who are recruited from a pool of eligible participants, and (2) fidelity of TDM, defined as the degree to which TDM as a test is delivered as intended, from accurate sample collection, sample processing to result availability. Secondary outcomes include target attainment, uptake of TDM-guided dosing and incidence of neurotoxicity, hepatotoxicity and nephrotoxicity. Ethics and dissemination: This study has been approved by the Alfred Hospital human research ethics committee, Office of Ethics and Research Governance (reference: Project No. 565/22; date of approval: 22/11/2022). Prospective consent will be obtained and the study will be conducted in accordance with the Declaration of Helsinki. The finalised manuscript, including aggregate data, will be submitted for publication in a peer reviewed journal. ADAPT-TDM will determine whether beta-lactam TDM-guided dose adaptation is reproducible and feasible and provide important information required to implement this intervention in a phase III trial. Trial registration number: Australian New Zealand Clinical Trials Registry, ACTRN12623000032651.

Revolutionizing Daptomycin Dosing: A Single 7-11 Hour Sample for Pragmatic Application

Daptomycin Exposure Prediction With a Limited Sampling Strategy

Daptomycin Dosage Optimization in Renal Impairment Using Model-Informed Precision Dosing

Limited sampling approach for model‐informed precision dosing of daptomycin to rapidly achieving the target area under the concentration‐time curve: A simulation study

Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic/Pharmacodynamic Investigation

A Machine Learning Algorithm to Predict the Starting Dose of Daptomycin

Population pharmacokinetics of intravenous daptomycin in critically ill patients: implications for selection of dosage regimens

Pharmacokinetics and safety of daptomycin administered subcutaneously in healthy volunteers: a single-blinded randomized crossover trial

Intraperitoneal daptomycin dosing for peritonitis may be inadequate: a Monte Carlo simulation approach to optimize dosing and outcomes

Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment

Model‐informed precision dosing of vancomycin for rapid achievement of target area under the concentration‐time curve: A simulation study

A machine learning approach to predict daptomycin exposure from two concentrations based on Monte Carlo simulations

Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment

Adaptive Dose Modification for Phase I Clinical Trials

Stability-indicating HPLC method optimization using quality by design with design of experiments approach for quantitative estimation of organic related impurities of Doripenem in pharmaceutical formulations

Assessing the stability of daptomycin in icodextrin-based peritoneal dialysis solution

Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring

Dose optimization and target attainment of vancomycin in children

Dynamic Compound-Dependent Acoustic Transfer to Investigate Inhibitor Reversibility

A high performance liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of 10 drug compounds commonly used for antimicrobial therapy in plasma and serum of critically ill patients: Method optimization, validation, cross-validation and clinical application

Bioanalysis of six antibiotics from volumetric microsamples: a new tool for precision dosing in critically ill children